Loading..

Sarepta Therapeutics, Inc. (SRPT) Report Analysis

Corporate Events

Neutral

Sarepta Therapeutics, Inc. - Special Call

2022-06-23 20:01:00

Sarepta Therapeutics, Inc. - Special Call

Positive

Sarepta Therapeutics, Inc. Provides Update on S...

2022-06-23 20:01:00

Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen),...

Neutral

Parent Project Muscular Dystrophy, 2022 Annual ...

2022-06-09 05:00:00

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022. Venu...

Negative

Sarepta Therapeutics, Inc. Appoints Michael Cha...

2022-06-02 20:05:00

Sarepta Therapeutics, Inc. announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chamber...

Neutral

Sarepta Therapeutics, Inc. Presents at Goldman ...

2022-06-02 12:30:00

Sarepta Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM. Venue: Terranea Resort, R...

Neutral

Sarepta Therapeutics, Inc. Presents at DIA Glob...

2022-05-28 18:13:00

Sarepta Therapeutics, Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Nicole...

Neutral

Sarepta Therapeutics, Inc. to Report Q1, 2022 R...

2022-04-27 12:30:00

Sarepta Therapeutics, Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

Sarepta Therapeutics, Inc., Q1 2022 Earnings Ca...

2022-04-27 12:30:00

Sarepta Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Sarepta Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-25 20:19:00

Annual General Meeting

Neutral

Sarepta Therapeutics, Inc., Annual General Meet...

2022-04-25 20:19:00

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022, at 09:00 Eastern Daylight. Agenda: To elect, as Class I directors to hold of...

Neutral

Sarepta Therapeutics, Inc. Presents at TIDES (O...

2022-04-23 17:57:00

Sarepta Therapeutics, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United Stat...

Neutral

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Th...

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Hanson Wade Limited, 2nd Gene Therapy Medical A...

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Gene Therapy Medical Affairs Summit, Apr 19, 2022 through Apr 21, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Sarepta Therapeutics, Inc. Presents at 2nd Gene...

2022-04-06 17:15:00

Sarepta Therapeutics, Inc. Presents at 2nd Gene Therapy Medical Affairs Summit, Apr-19-2022 . Venue: Boston, Massachusetts, United States. Spe...

Negative

Sarepta Therapeutics, Inc. Announces Not Stand ...

2022-04-06 10:09:00

On March 31, 2022, Mary Ann Gray, Ph.D., informed the board of directors of Sarepta Therapeutics, Inc. that she has elected to not stand for r...

Neutral

Sarepta Therapeutics, Inc. Presents at Bank of ...

2022-03-22 05:03:00

Sarepta Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM. Venue: Encore Hotel, 3121 Las Vegas B...

Neutral

Sarepta Therapeutics, Inc. Presents at Guggenhe...

2022-03-02 21:30:00

Sarepta Therapeutics, Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar-31-2022 12:00 PM.

Neutral

Guggenheim Securities, LLC, Guggenheim Healthca...

2022-02-24 12:30:00

Guggenheim Securities, LLC, Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar 31, 2022 through Apr 01, 2022.

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Positive

Sarepta Therapeutics and GenEdit Share Progress...

2022-02-01 13:00:00

Sarepta Therapeutics, Inc. and GenEdit, Inc. announced a research collaboration and option agreement under which the companies are employing G...

Neutral

Drug Information Association, Inc., DIA Global ...

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

Negative

Sarepta Therapeutics Names Louise Rodino-Klapac...

2021-11-17 13:31:00

Sarepta Therapeutics, Inc. announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific o...

Negative

Sarepta Therapeutics Appoints Stephen L. Mayo t...

2021-11-17 13:30:00

Sarepta Therapeutics, Inc. announced the appointment of Stephen L. Mayo, Ph.D., to its Board of Directors, effective immediately. Dr. Mayo is ...

Neutral

Sarepta Therapeutics, Inc. Announces Revenue Gu...

2021-11-03 20:01:00

Sarepta Therapeutics, Inc. announced revenue guidance for the year 2021. Its full-year product revenue guidance by $40 million to between $605...

Neutral

Sarepta Therapeutics, Inc. Presents at 4th Annu...

2021-11-02 20:30:00

Sarepta Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 01:25 PM.

Neutral

Sarepta Therapeutics, Inc. Presents at Barclays...

2021-11-02 20:30:00

Sarepta Therapeutics, Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 03:00 PM.

Neutral

Sarepta Therapeutics, Inc., Q3 2021 Earnings Ca...

2021-10-27 12:33:00

Sarepta Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Sarepta Therapeutics, Inc. to Report Q3, 2021 R...

2021-10-27 12:33:00

Sarepta Therapeutics, Inc. announced that they will report Q3, 2021 results After-Market on Nov 03, 2021

Neutral

Barclays PLC, Barclays Gene Editing & Gene Ther...

2021-10-20 20:00:00

Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021.

Negative

Sarepta Therapeutics, Inc. has completed a Foll...

2021-10-13 00:00:00

Sarepta Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $500.00004 million. Security Name: Common Stock Secu...

Negative

Certain Restricted Stock Units of Sarepta Thera...

2021-10-13 00:00:00

Certain Restricted Stock Units of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021. These Restricted Stock ...

Negative

Certain Common Stock of Sarepta Therapeutics, I...

2021-10-13 00:00:00

Certain Common Stock of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021. These Common Stock will be under ...

Negative

Certain Stock Options of Sarepta Therapeutics, ...

2021-10-13 00:00:00

Certain Stock Options of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021. These Stock Options will be unde...

Negative

Sarepta Therapeutics, Inc. has filed a Follow-o...

2021-10-12 00:00:00

Sarepta Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type:...

Neutral

Sarepta Therapeutics, Inc. Reports Preliminary ...

2021-10-12 00:00:00

Sarepta Therapeutics, Inc. announced preliminary revenue guidance for the third quarter ended September 30, 2021. For the third quarter, the c...

Positive

Sarepta Therapeutics’ SRP-9001 Shows Sustained ...

2021-10-11 13:13:00

Sarepta Therapeutics, Inc. shared new analyses and functional data from its SRP-9001 development program and details of Study SRP-9001-301, kn...

Positive

Sarepta Therapeutics, Inc. Opens Genetic Therap...

2021-10-04 20:30:00

Sarepta Therapeutics, Inc. celebrated the grand opening of the Genetic Therapies Center of Excellence (GTCOE), its new research facility in Co...

Neutral

Sarepta Therapeutics, Inc. - Special Call

2021-10-04 11:00:00

SRP-9001 Micro-dystrophin R&D Day

Positive

Sarepta Therapeutics Announces Initiation of EM...

2021-10-04 11:00:00

Sarepta Therapeutics, Inc. announced the initiation, in partnership with Roche, in the U.S. and countries around the world, of study SRP-9001-...

Neutral

Sarepta Therapeutics, Inc. Presents at 30th Ann...

2021-10-01 10:34:00

Sarepta Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 12:10 PM. Venue: Rancho Palos Verdes, Cali...

Positive

Sarepta Therapeutics, Inc. to Initiate Part B o...

2021-09-27 12:35:00

Sarepta Therapeutics, Inc. announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans ...

Negative

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropp...

2021-09-18 00:00:00

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from FTSE All-World Index (USD)

Neutral

Sarepta Therapeutics, Inc. Presents at Morgan S...

2021-09-07 20:30:00

Sarepta Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 01:15 PM. Venue: New Windsor, Unit...

Neutral

Sarepta Therapeutics, Inc. Presents at Cantor G...

2021-09-07 20:30:00

Sarepta Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM. Venue: New York, United States.

Neutral

Sarepta Therapeutics, Inc. Presents at Baird Gl...

2021-08-26 17:20:00

Sarepta Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 10:15 AM. Speakers: Douglas S. Ingram, President, ...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Sarepta Therapeutics, Inc. Presents at World Or...

2021-08-20 20:24:00

Sarepta Therapeutics, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-27-2021 11:35 AM. Venue: Gaylord National Resort & Convention ...

Neutral

Terrapinn Holdings Ltd, World Orphan Drug Congr...

2021-08-20 17:31:00

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention C...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Positive

Sarepta Therapeutics, Inc. Raises Product Reven...

2021-08-04 20:05:00

Sarepta Therapeutics, Inc. raised product revenue guidance for full year of 2021. For the year, the company expects product revenue ranging be...

Neutral

Sarepta Therapeutics, Inc. Executes Licensing A...

2021-08-04 12:30:00

Sarepta Therapeutics, Inc. announced that upon completion of a number of preclinical and safety studies, it had executed an exclusive license ...

Neutral

Sarepta Therapeutics, Inc. to Report Q2, 2021 R...

2021-07-28 12:30:00

Sarepta Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

Sarepta Therapeutics, Inc., Q2 2021 Earnings Ca...

2021-07-28 12:30:00

Sarepta Therapeutics, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Sarepta Therapeutics, Inc. - Special Call

2022-06-23 20:01:00

Sarepta Therapeutics, Inc. - Special Call

Positive

Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

2022-06-23 20:01:00

Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. The hold in Part B of Study 5051-201, also known as MOMENTUM, follows a serious adverse event of hypomagnesemia. FDA is requesting information on all cases of hypomagnesemia, including a small number of non-serious grade 2 cases, and to assess the adequacy of the risk mitigation and safety monitoring plan. In the next few days the company will respond to the Agency with this information and proposed changes to the monitoring plan. SRP-5051 is an investigational agent using Sarepta’s PPMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally shortened functional dystrophin protein. PPMO is Sarepta’s next-generation chemistry platform designed around a proprietary cell-penetrating peptide conjugated to the PMO backbone, with the goal of increasing tissue penetration, increasing exon skipping, and significantly increasing dystrophin production. Around 13% of DMD patients have mutations that make them amenable to skipping exon 51. If successful, the PPMO offers the potential for improved efficacy and less frequent dosing for patients. MOMENTUM is Phase 2, multi-arm, ascending dose study of SRP-5051, infused monthly and will assess dystrophin protein levels in skeletal muscle tissue following SRP-5051 treatment. The study will enroll up to 60 participants, both ambulant and non-ambulant, between the ages of 7 to 21 at sites in the U.S., Canada, and the European Union. The study will also assess safety and tolerability.

Neutral

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022

2022-06-09 05:00:00

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022. Venue: Scottsdale, Arizona, United States.

Negative

Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors

2022-06-02 20:05:00

Sarepta Therapeutics, Inc. announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers and Dr. Boor bring distinct and invaluable experience to the Sarepta board that will help guide the company on its mission to change the course of life-threatening rare diseases. Mr. Chambers co-founded Aldevron, based in Fargo, N.D., in 1998, and served as its chief executive officer for more than 20 years before serving as Executive Chairman of the Board until 2021 when Aldevron was acquired for $9.6 billion. As founder, Chambers oversaw the growth of Aldevron into a world-class service organization, specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe. Chambers currently serves on the Board of Directors at Calviri, Inc. In 2018, Chambers was named one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs.  He earned his bachelor’s degree in biotechnology, microbiology, and chemistry from North Dakota State University. Dr. Boor is the Dean of the Graduate School and Vice Provost for Graduate Education at Cornell University. Previously, Dr. Boor served as the Ronald P. Lynch Dean of the College of Agriculture and Life Sciences (CALS) at Cornell.  She earned a bachelor’s degree in food science from Cornell University, a master’s degree in food science from the University of Wisconsin and a Ph.D. in microbiology from the University of California, Davis. She joined the Cornell Food Science department as assistant professor in 1994, became its first tenured female faculty member in 2000, and led as department chair from 2007-2010. Dr. Boor serves on the Board of Directors for Seneca Foods Corporation, International Flavors and Fragrances, the United States-Israel Binational Agricultural Research and Development (BARD) Fund, and the Foundation for Food and Agriculture Research (FFAR). She serves on the Science Board for the US Food and Drug Administration and on the New York State Southern Tier Regional Economic Development Council.

Neutral

Sarepta Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM

2022-06-02 12:30:00

Sarepta Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Sarepta Therapeutics, Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022

2022-05-28 18:13:00

Sarepta Therapeutics, Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Nicole Damour, Director.

Neutral

Sarepta Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

2022-04-27 12:30:00

Sarepta Therapeutics, Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

Sarepta Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-27 12:30:00

Sarepta Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Sarepta Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-25 20:19:00

Annual General Meeting

Neutral

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

2022-04-25 20:19:00

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022, at 09:00 Eastern Daylight. Agenda: To elect, as Class I directors to hold office until the 2024 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn Boor, Ph.D., Michael Chambers, Douglas S. Ingram, and Hans Wigzell, M.D., Ph.D.; to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation; to approve an amendment to the Company’s 2018 Equity Incentive Plan to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 10,687,596 shares; to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.

Neutral

Sarepta Therapeutics, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022

2022-04-23 17:57:00

Sarepta Therapeutics, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United States. Speakers: Carlos Martinez, Associate Director Manufacturing Sciences & Technology.

Neutral

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Hanson Wade Limited, 2nd Gene Therapy Medical Affairs Summit, Apr 19, 2022 through Apr 21, 2022

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Gene Therapy Medical Affairs Summit, Apr 19, 2022 through Apr 21, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Sarepta Therapeutics, Inc. Presents at 2nd Gene Therapy Medical Affairs Summit, Apr-19-2022

2022-04-06 17:15:00

Sarepta Therapeutics, Inc. Presents at 2nd Gene Therapy Medical Affairs Summit, Apr-19-2022 . Venue: Boston, Massachusetts, United States. Speakers: Kathrin Kucharski, Senior Director Medical Managed Care.

Negative

Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director

2022-04-06 10:09:00

On March 31, 2022, Mary Ann Gray, Ph.D., informed the board of directors of Sarepta Therapeutics, Inc. that she has elected to not stand for re-election and will complete her term on the board at the conclusion of the company’s 2022 annual meeting of stockholders. Dr. Gray’s decision to not stand for re-election was not because of a disagreement with the company on any matter relating to the Company’s operations, policies, or practices.

Neutral

Sarepta Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM

2022-03-22 05:03:00

Sarepta Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Douglas S. Ingram, President, CEO & Director.

Neutral

Sarepta Therapeutics, Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar-31-2022 12:00 PM

2022-03-02 21:30:00

Sarepta Therapeutics, Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar-31-2022 12:00 PM.

Neutral

Guggenheim Securities, LLC, Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar 31, 2022 through Apr 01, 2022

2022-02-24 12:30:00

Guggenheim Securities, LLC, Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar 31, 2022 through Apr 01, 2022.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Positive

Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases

2022-02-01 13:00:00

Sarepta Therapeutics, Inc. and GenEdit, Inc. announced a research collaboration and option agreement under which the companies are employing GenEdit’s NanoGalaxy platform and Sarepta’s gene editing technology to develop gene editing therapeutics for the treatment of neuromuscular diseases. As part of the agreement, Sarepta obtains exclusive option rights to license polymer nanoparticles developed by GenEdit in the collaboration for up to four neuromuscular indications selected by Sarepta. Initial in vivo results from the research collaboration between GenEdit and Sarepta have demonstrated the potential of GenEdit’s polymer nanoparticles to deliver therapeutic cargo to specific muscle tissue after systemic administration to allow for targeted, non-viral systemic delivery of genetic medicines. The research collaboration and option agreement commenced in December 2020. Gene editing has the potential to revolutionize the treatment of diseases caused by genetic mutations by permanently modifying the genes that lead to disease. Sarepta is pursuing a variety of approaches to genetic medicine, including gene editing, as a potentially curative treatment for rare neuromuscular diseases. GenEdit has demonstrated in preclinical studies that its NanoGalaxy platform can selectively deliver to different tissues a variety of functional genetic medicine cargos, including CRISPR-Cas9 ribonucleoprotein, for targeted in vivo gene editing. In addition to research payments, under the terms of the collaboration and option agreement, GenEdit may receive up to $57 million in near-term payments and is also eligible for significant future development, regulatory and commercial milestones and tiered royalties ranging from upper-single to low-double digits on future product sales. Additional financial details were not disclosed.

Neutral

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

Negative

Sarepta Therapeutics Names Louise Rodino-Klapac as Head of Research and Development

2021-11-17 13:31:00

Sarepta Therapeutics, Inc. announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific officer, has been named the Company’s head of research and development (R&D) and will continue to serve in the role of chief scientific officer. Gilmore O’Neill, M.B., M.M.Sc., who has served as head of R&D since 2018, will leave the Company at the end of November and remain in a consulting capacity until March 31, 2022.

Negative

Sarepta Therapeutics Appoints Stephen L. Mayo to Its Board of Directors

2021-11-17 13:30:00

Sarepta Therapeutics, Inc. announced the appointment of Stephen L. Mayo, Ph.D., to its Board of Directors, effective immediately. Dr. Mayo is currently the Bren Professor of Biology and Chemistry at California Institute of Technology (Caltech), and serves on the board of directors for Merck and on the scientific advisory board of Rubryc Therapeutics. At Caltech, Dr. Mayo holds joint appointments in the Division of Biology and Biological Engineering and the Division of Chemistry and Chemical Engineering. He joined the Caltech faculty in 1992 and served as Vice Provost for Research from 2007 to 2010 and Chair of the Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo's research focuses on the development of computational approaches to protein engineering – a field that has broad applications ranging from advanced biofuels to human therapeutics. In 2004, he was elected to the U.S. National Academy of Sciences for his pioneering contributions in the field of protein design. Dr. Mayo has co-founded several companies: Molecular Simulations Inc. (now Biovia), Xencor, and Protabit, where he serves on the scientific advisory board. In addition to his academic and private-sector work, Dr. Mayo has served as an elected Board Member at the American Association for the Advancement of Science (2010-2014) and served as a presidential appointee to National Science Foundation’s National Science Board (2013-2018). Dr. Mayo received an undergraduate degree in chemistry from the Pennsylvania State University, and a Ph.D. in chemistry from Caltech. He completed postdoctoral work at both UC Berkeley and the Stanford University School of Medicine.

Neutral

Sarepta Therapeutics, Inc. Announces Revenue Guidance for the Year 2021

2021-11-03 20:01:00

Sarepta Therapeutics, Inc. announced revenue guidance for the year 2021. Its full-year product revenue guidance by $40 million to between $605 million to $615 million.

Neutral

Sarepta Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 01:25 PM

2021-11-02 20:30:00

Sarepta Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 01:25 PM.

Neutral

Sarepta Therapeutics, Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 03:00 PM

2021-11-02 20:30:00

Sarepta Therapeutics, Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 03:00 PM.

Neutral

Sarepta Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-27 12:33:00

Sarepta Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Sarepta Therapeutics, Inc. to Report Q3, 2021 Results on Nov 03, 2021

2021-10-27 12:33:00

Sarepta Therapeutics, Inc. announced that they will report Q3, 2021 results After-Market on Nov 03, 2021

Neutral

Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021

2021-10-20 20:00:00

Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021.

Negative

Sarepta Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $500.00004 million.

2021-10-13 00:00:00

Sarepta Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $500.00004 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,172,840 Price\Range: $81 Discount Per Security: $3.65

Negative

Certain Restricted Stock Units of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021.

2021-10-13 00:00:00

Certain Restricted Stock Units of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021. These Restricted Stock Units will be under lockup for 61 days starting from 13-OCT-2021 to 13-DEC-2021. Details: Company's directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which the company and each of these persons for a period of 60 days, after the date of this prospectus supplement, may not, subject to limited exceptions, without the prior written consent of the underwriters i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of the company's common stock or any other securities convertible into or exercisable or exchangeable for shares of the company's common stock or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of shares of the company's common stock or such other securities

Negative

Certain Common Stock of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021.

2021-10-13 00:00:00

Certain Common Stock of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021. These Common Stock will be under lockup for 61 days starting from 13-OCT-2021 to 13-DEC-2021. Details: Company's directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which the company and each of these persons for a period of 60 days, after the date of this prospectus supplement, may not, subject to limited exceptions, without the prior written consent of the underwriters i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of the company's common stock or any other securities convertible into or exercisable or exchangeable for shares of the company's common stock or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of shares of the company's common stock or such other securities

Negative

Certain Stock Options of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021.

2021-10-13 00:00:00

Certain Stock Options of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2021. These Stock Options will be under lockup for 61 days starting from 13-OCT-2021 to 13-DEC-2021. Details: Company's directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which the company and each of these persons for a period of 60 days, after the date of this prospectus supplement, may not, subject to limited exceptions, without the prior written consent of the underwriters i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of the company's common stock or any other securities convertible into or exercisable or exchangeable for shares of the company's common stock or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of shares of the company's common stock or such other securities

Negative

Sarepta Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

2021-10-12 00:00:00

Sarepta Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock

Neutral

Sarepta Therapeutics, Inc. Reports Preliminary Revenue Guidance for the Third Quarter Ended September 30, 2021

2021-10-12 00:00:00

Sarepta Therapeutics, Inc. announced preliminary revenue guidance for the third quarter ended September 30, 2021. For the third quarter, the company expects its net product revenues for the quarter to be approximately $166.9 million, compared to net product revenues of $121.4 million for the same period of 2020.

Positive

Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

2021-10-11 13:13:00

Sarepta Therapeutics, Inc. shared new analyses and functional data from its SRP-9001 development program and details of Study SRP-9001-301, known as EMBARK, its global pivotal Phase 3 trial of SRP-9001 for the treatment of Duchenne muscular dystrophy. SRP-9001, being developed in partnership with Roche, is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. In new analyses presented at SRP-9001 Micro-dystrophin Day,results from participants treated with SRP-9001 in Study SRP-9001-101 (n=4, ages 4 to 7) found that participants in Study 101 improved 8.6 points on the North Star Ambulatory Assessment (NSAA) compared to a matched natural history cohort three years following a single administration of SRP-9001 (p<0.0001). In Study SRP-9001-102, SRP-9001-treated participants ages 6 to 7 (n=12) had a positive 2.9-point difference on NSAA change from baseline compared to a matched natural history control (p=0.0129). In addition, the first functional results were presented from Study SRP-9001-103 (ENDEAVOR), which uses commercially representative SRP-9001 material. Results from the first 11 participants in Cohort 1, ages 4 to 7, demonstrated a 3.0-point improvement from baseline on NSAA six months after treatment.

Positive

Sarepta Therapeutics, Inc. Opens Genetic Therapies Center of Excellence in Columbus, Ohio

2021-10-04 20:30:00

Sarepta Therapeutics, Inc. celebrated the grand opening of the Genetic Therapies Center of Excellence (GTCOE), its new research facility in Columbus, Ohio. The 85,000 square foot facility expands Sarepta’s research and development capabilities and footprint, which includes sites in Cambridge, Andover and Burlington, Mass. With more than 70 employees and plans to double the number of employees by the end of 2022, the Center is focused on discovery, pre-clinical and clinical development supporting Sarepta’s pipeline of genetic medicines which includes RNA, gene therapy and gene editing programs. The Center also supports process development and optimization work that enables the transition from clinical-scale to commercial-scale manufacturing, a critical task facing companies developing gene therapies. Among the guests joining the Sarepta team for a dedication, ribbon-cutting ceremony and facility tours: The Honorable Jon Husted, Ohio’s Lieutenant Governor; Pat Furlong, president and chief executive officer, Parent Project Muscular Dystrophy (PPMD); Jessica Evans, assistant director, The Speak Foundation; local officials; and luminaries from Columbus’ growing biotechnology sector. At the event, Sarepta also announced a $20,000 donation to the Ronald McDonald House Charities of Central Ohio, with Dee Anders, chief executive officer and executive director, Ronald McDonald House Charities of Central Ohio, present to accept.

Neutral

Sarepta Therapeutics, Inc. - Special Call

2021-10-04 11:00:00

SRP-9001 Micro-dystrophin R&D Day

Positive

Sarepta Therapeutics Announces Initiation of EMBARK, Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

2021-10-04 11:00:00

Sarepta Therapeutics, Inc. announced the initiation, in partnership with Roche, in the U.S. and countries around the world, of study SRP-9001-301, also known as EMBARK, a pivotal study of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.

Neutral

Sarepta Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 12:10 PM

2021-10-01 10:34:00

Sarepta Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 12:10 PM. Venue: Rancho Palos Verdes, California, United States. Speakers: Douglas S. Ingram, President, CEO & Director.

Positive

Sarepta Therapeutics, Inc. to Initiate Part B of Momentum Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

2021-09-27 12:35:00

Sarepta Therapeutics, Inc. announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter. MOMENTUM is a global trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. The study will enroll between 20-40 patients between ages 7 to 21 amenable to exon 51 skipping who are naïve to SRP-5051. Additionally, those previously dosed in Study 5051-201, Part A or Study 5051-102 who meet the entrance criteria will be eligible to participate. Both ambulatory and non-ambulatory patients are eligible for participation. The Company will submit the protocol in the next week. MOMENTUM is a multi-arm, ascending dose study of SRP-5051, infused monthly and will assess dystrophin protein level in skeletal muscle tissue following SRP-5051 treatment. The study will enroll both ambulant and non-ambulant patients between the ages of 7 to 21 at sites in the U.S., Canada, Australia, and European Union. The study will also assess safety and tolerability. In May of this year, the Company announced results from Part A of the MOMENTUM study showing that after 12 weeks, 30 mg/kg of SRP-5051 dosed monthly resulted in 18 times the exon skipping and eight times the dystrophin production as eteplirsen, dosed weekly for 24 weeks. Reversible hypomagnesemia was identified in patients taking SRP-5051. The protocol for Part B of MOMENTUM will include magnesium supplementation and monitoring of magnesium levels.

Negative

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from FTSE All-World Index (USD)

2021-09-18 00:00:00

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from FTSE All-World Index (USD)

Neutral

Sarepta Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 01:15 PM

2021-09-07 20:30:00

Sarepta Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 01:15 PM. Venue: New Windsor, United States.

Neutral

Sarepta Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM

2021-09-07 20:30:00

Sarepta Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM. Venue: New York, United States.

Neutral

Sarepta Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 10:15 AM

2021-08-26 17:20:00

Sarepta Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 10:15 AM. Speakers: Douglas S. Ingram, President, CEO & Director, Ian Michael Estepan, Executive VP & CFO.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Sarepta Therapeutics, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-27-2021 11:35 AM

2021-08-20 20:24:00

Sarepta Therapeutics, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-27-2021 11:35 AM. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States. Speakers: Stacey Frisk, Global Policy, Government & Patient Affairs.

Neutral

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021

2021-08-20 17:31:00

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Positive

Sarepta Therapeutics, Inc. Raises Product Revenue Guidance for Full Year of 2021

2021-08-04 20:05:00

Sarepta Therapeutics, Inc. raised product revenue guidance for full year of 2021. For the year, the company expects product revenue ranging between $565 million to $575 million.

Neutral

Sarepta Therapeutics, Inc. Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A

2021-08-04 12:30:00

Sarepta Therapeutics, Inc. announced that upon completion of a number of preclinical and safety studies, it had executed an exclusive license agreement for an investigational gene therapy candidate, calpain 3 (CAPN-3), to treat Limb-girdle muscular dystrophy type 2A (LGMD2A), developed by the Abigail Wexner Research Institute at Nationwide Children’s Hospital (Nationwide Children’s). LGMDs represent a group of distinct genetic neuromuscular diseases with a generally common set of symptoms, including progressive, debilitating weakness and wasting that begins in muscles around the hips and shoulders before progressing to muscles in the arms and legs. Many LGMD sub-types are significantly life-limiting and often life-ending diseases. Also known as calpainopathy, LGMD2A is caused by mutations in the CAPN-3 gene and is the most common type of LGMD, accounting for almost a third of cases.

Neutral

Sarepta Therapeutics, Inc. to Report Q2, 2021 Results on Aug 04, 2021

2021-07-28 12:30:00

Sarepta Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

Sarepta Therapeutics, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-28 12:30:00

Sarepta Therapeutics, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Fundamental Summary

Sarepta Therapeutics published its Q1 report on 2022-05-04 with positive results, but no significant factors particularly remarkable relative to its peers. It is highly likely that it will be mostly tethered to market performance and sector movements for the near term. Overall, Sarepta Therapeutics's growth and income factors are trending positively, and we, therefore, give Sarepta Therapeutics an overall grade of 73 and a HOLD recommendation.

Sarepta Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 210.83 million compared to USD 146.93 million a year ago. Net loss was USD 105.03 million compared to USD 167.25 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 2.1 a year ago. Diluted loss per share from continuing operations was USD 1.2 compared to USD 2.1 a year ago.

Business Description

Sarepta Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sector Overview

Sarepta Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Sarepta Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 3,056.2 -2.9% 69
Liabilities 2,199.3 -0.9% 68
Price to Book 7.5 -11.9% 58
Cash & Equivalents 1,233.9 -41.7% 41
Equity 856.9 -7.7% 49
EBITDA -304.2 16.4% 89
Total Revenues 765.8 9.1% 49
Parameter Value Change Score
Return on Equity -51.2 -3.3% 55
Net Cashflow -247.4 -140.3% 85
Capital Expenditure -22.9 40.5% 95
Asset Turnover 0.3 14.9% 87
Free Cashflow -3.4 26.7% 89

* All values are TTM

The below chart reflects Sarepta Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Sarepta Therapeutics's peer average final assessment score stands on 63.0, Sarepta Therapeutics's score is 73.

  •  SRPT
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 14 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 15 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 16 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 17 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 18 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Sarepta Therapeutics's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Sarepta Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.

Neutral 62
Close Price 74.67
52W Low 62.69
52W High 99.42
5D MA 73.26
50D MA 71.17
200D MA 79.26
MACD 0.49
RSI 45.48
STOCH 88.02

Balance Sheet Analysis

A few metrics from Sarepta Therapeutics's current balance sheet were especially concerning: Cash & Equivalents and Equity. Sarepta Therapeutics reported concerning cash and cash equivalents metrics in this filing. Specifically, they reported that cash and cash equivalents were 1233.9, representing a -41.7% change from the last period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 41. Also, Sarepta Therapeutics management produced disappointing equity metrics this period, which stood at 856.9, representing a -7.7% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Its equity movement component, therefore, received a grade of 49. That said, one metric, Assets, stood out as strongly positive. Sarepta Therapeutics assets on their balance sheet, moved to 3056.2, which is a -2.9% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its asset component earned a score of 69. Therefore, the company's balance sheet earned a grade of 58.

Parameter Value Change Score
Assets 3,056.2 -2.9% 69
Liabilities 2,199.3 -0.9% 68
Price to Book 7.5 -11.9% 58
Cash & Equivalents 1,233.9 -41.7% 41
Equity 856.9 -7.7% 49
* All values are TTM

The below chart describes Sarepta Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Sarepta Therapeutics received a balance sheet score of 58, the average of its peers stands on 65.0.

  •  SRPT
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 13 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 14 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 15 1
Alkermes plc 5.0B 63 66 46 54 71 62 16 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 17 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 18 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, Sarepta Therapeutics's critical income statement metrics appear to strongly support positive growth going forward. Sarepta Therapeutics reported impressive EBITDA this period. At filing, EBITDA was reported as -304.2, representing 16.4% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Consequently, their EBITDA movement received a grade of 89. Also, Sarepta Therapeutics's reported return on equity (ROE) ratio was -51.2, representing a change of -3.3%. Its return factor metrics are even more remarkable when compared to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 55. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Sarepta Therapeutics's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. As a result, their revenue efficiency earned a score of 49. Therefore, we scored its income statement a 78.

Parameter Value Change Score
EBITDA -304.2 16.4% 89
Total Revenues 765.8 9.1% 49
Return on Equity -51.2 -3.3% 55
* All values are TTM

The below chart describes Sarepta Therapeutics's performance as reflected on its income statement with respect to its peers. While Sarepta Therapeutics received a income statement score of 78 , the average of its peers stands on 65.0.

  •  SRPT
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 14 1
Ascendis Pharma A/S 5.2B 38 68 46 54 15 1
Alkermes plc 5.0B 69 55 81 62 16 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 17 1
Novavax, Inc. 4.0B 41 89 54 75 18 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two metrics jump up as the most significant positive drivers of the cash flow's strength in Sarepta Therapeutics's recent report: Capex and Free Cash flow. Sarepta Therapeutics's management was effective in improving its CapEx, which now sits at -22.9 and represents 40.5% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 95. Also, Sarepta Therapeutics's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Sarepta Therapeutics recorded free cash flow of -3.4, which represents a 26.7% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. The company's free cash flow movement, therefore, received a grade of 89. At the same time, one critical cash flow metric, Net Cash Flow, was notably weak. Sarepta Therapeutics's net cash flow metrics were -247.4 according to their current filing, which represents a -140.3% change from the previous report. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Sarepta Therapeutics's stock price going forward. Hence, their net cash flow earned a score of 85. Therefore, we scored their cash flow a 93.

Parameter Value Change Score
Net Cashflow -247.4 -140.3% 85
Capital Expenditure -22.9 40.5% 95
Asset Turnover 0.3 14.9% 87
Free Cashflow -3.4 26.7% 89
* All values are TTM

The below chart describes Sarepta Therapeutics's performance as reflected on its cash flow with respect to its peers. While Sarepta Therapeutics received a cash flow score of 93, the average of its peers stands on 66.0.

  •  SRPT
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 13 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 14 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 15 1
Alkermes plc 5.0B 89 95 76 80 92 16 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 17 1
Novavax, Inc. 4.0B 62 38 63 54 60 18 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.